VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation
SAN FRANCISCO, September 15, 2008 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. , a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome (ACS) and in patients undergoing carotid endarterectomy (CEA) surgery, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, taking place November 8-12 in New Orleans, LA.
Given AHA's embargo policy, the company will announce the proof of concept data from its CEA and ACS trials concurrent with the AHA sessions.
The presentation details are as follows: Date/Time: Sunday, November 9, 2008: 5:45 p.m. CDT Location: Ernest N. Morial Convention Center, Room 275-277 Session: Cardiovascular Seminar: Translational Trials and Strategies: First in Man Title: Three Months of Treatment with 5- Lipoxygenase Inhibitor VIA-2291 in Patients with Recent Acute Coronary Syndrome Presented by: Jean-Claude Tardif, M.D., Professor and Director, Montreal Heart Institute, Montreal, Canada Date/Time: Sunday, November 9, 2008: 6:00 p.m. CDT Location: Ernest N. Morial Convention Center, Room 275-277 Session: Cardiovascular Seminar: Translational Trials and Strategies: First in Man Title: Three Months of Treatment with 5-Lipoxygenase Inhibitor VIA- 2291 in Patients Scheduled for Elective Carotid Endarterectomy Surgery Presented by: Tilmann M Brotz, Ph.D., Vice President of Pre-Clinical Research and Development, VIA Pharmaceuticals
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.
This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to:
-- our ability to obtain necessary financing; -- our ability to control our operating expenses; -- our ability to recruit and enroll patients for the FDG-PET clinical trial; -- failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials; -- our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials; -- complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays; -- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- the outcome of any legal proceedings; -- our ability to obtain necessary FDA approvals; -- our ability to successfully commercialize VIA-2291; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 on file with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.
CONTACT: James G. Stewart, Senior Vice President and Chief FinancialOfficer of VIA Pharmaceuticals, Inc., +1-415-283-2204; or Media, DanielleBertrand of WeissComm Partners, +1-415-946-1056, ;or Investors, San Francisco, Ian Clements or Lauren Glaser,+1-415-392-3385, or New York City, Brian Korb, +1-646-378-2923, all of TheTrout Group for VIA Pharmaceuticals, Inc. email@example.com
Web site: http://www.viapharmaceuticals.com/
Ticker Symbol: (NASDAQ-NMS:VIAP)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: September 2008